Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits

06/24/2022 | 07:18am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BIOGEN INC.
08/03Eisai presents new findings on lecanemab's investigational subcutaneous formulation and..
PR
07/28The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII..
GL
07/28The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII..
AQ
07/27Biogen Inc. - FDA Accepts Biogen's New Drug Application and Grants Priority Review of T..
AQ
07/26Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi..
MT
07/26Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi..
MT
07/26U.S. FDA accepts Biogen's ALS therapy for review
RE
07/26U.S. FDA grants priority review to Biogen's ALS drug
RE
07/26FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a ..
GL
07/26Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review o..
CI
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 995 M - -
Net income 2022 2 350 M - -
Net cash 2022 11,0 M - -
P/E ratio 2022 13,8x
Yield 2022 -
Capitalization 31 664 M 31 664 M -
EV / Sales 2022 3,17x
EV / Sales 2023 3,04x
Nbr of Employees 9 610
Free-Float 85,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 218,20 $
Average target price 238,38 $
Spread / Average Target 9,25%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-9.05%31 664
CSL LIMITED2.07%98 543
SAMSUNG BIOLOGICS CO.,LTD.-0.89%48 860
WUXI BIOLOGICS (CAYMAN) INC.-19.88%40 273
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.97%23 596
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.-10.15%17 868